Table 1.

Demographic data of patients with liver cirrhosis and bacteremia caused by extended-spectrum beta-lactamase Escherichia coli and non-extended-spectrum beta-lactamase Escherichia coli.

Variables	ESBLEC (n = 51)	NESBLEC (n = 51)	p Value
Age (year)	69.1 ± 13.8	67.3 ± 13.7	0.5
Male gender	27 (52.9%)	26 (55.6%)	0.8
Etiology of cirrhosis
Hepatitis B	13 (25.5%)	16 (17.7%)	0.5
Hepatitis C	23 (45.1%)	23 (45.1%)	1.0
Alcohol	11 (21.6%)	10 (19.6%)	0.8
Others	9 (17.7%)	7 (13.7%)	0.6
Serum albumin (mg/dL)	2.7 ± 0.6	2.7 ± 0.6	0.9
Serum total bilirubin (mg/dL)	3.0 ± 5.2	3.1 ± 3.6	0.9
Prothrombin time-prolonged (sec.)	3.2 ± 3.7	3.4 ± 3.1	0.8
Serum creatinine (mg/dL)	1.9 ± 1.7	1.7 ± 1.6	0.5
Ascites	28 (54.9%)	33 (64.7%)	0.4
Hepatic encephalopathy	8 (15.7%)	9 (17.6%)	0.8
Child–Pugh score	8.2 ± 2.2	8.9 ± 2.5	0.2
MELD a score	15.7 ± 7.2	15.6 ± 7.0	0.9
Diabetes	18 (35.3%)	26 (51.0%)	0.1
Cardiovascular disease	30 (58.8%)	24 (47.0%)	0.2
Heart failure	4 (7.8%)	3 (5.9%)	1.0
Sources of BSIs b
Primary bacteremia	12 (23.5%)	16 (31.4%)	0.4
Spontaneous bacterial peritonitis	6 (11.8%)	10 (19.6%)	0.3
Urinary tract infection	27 (52.9%)	13 (25.5%)	0.005
Intraabdominal infection	2 (3.9%)	7 (13.7%)	0.2
Biliary tract infection	3 (5.9%)	4 (7.8%)	1.0
Pneumonia	1 (2.0%)	1 (2.0%)	1.0
Healthcare associated risk
Prior admission	29 (56.9%)	20 (39.2%)	0.1
Urinary catheterization	5 (9.8%)	3 (5.9%)	0.7
Central venous line	3 (5.9%)	2 (3.9%)	1.0
Endotracheal tube	1 (2.0%)	0 (0%)	1.0
Nasogastric tube	3 (5.9%)	1 (2.0%)	0.6
Endoscopic therapy	2 (3.9%)	3 (5.9%)	1.0
Surgery	2 (3.9%)	1 (2.0%)	1.0
Antibiotics use within 3 months	22 (43.1%)	11 (21.6%)	0.02

^a MELD: model for end-stage liver disease. ^b BSIs: Bloodstream infections.